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Background
Antiretroviral therapy that reduces viral replication could limit the transmission of 
human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
Methods
In nine countries, we enrolled 1763 couples in which one partner was HIV-1–positive 
and the other was HIV-1–negative; 54% of the subjects were from Africa, and 50% 
of infected partners were men. HIV-1–infected subjects with CD4 counts between 
350 and 550 cells per cubic millimeter were randomly assigned in a 1:1 ratio to receive 
antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 
count or the onset of HIV-1–related symptoms (delayed therapy). The primary preven-
tion end point was linked HIV-1 transmission in HIV-1–negative partners. The pri-
mary clinical end point was the earliest occurrence of pulmonary tuberculosis, severe 
bacterial infection, a World Health Organization stage 4 event, or death.
Results
As of February 21, 2011, a total of 39 HIV-1 transmissions were observed (incidence 
rate, 1.2 per 100 person-years; 95% confidence interval [CI], 0.9 to 1.7); of these, 28 were 
virologically linked to the infected partner (incidence rate, 0.9 per 100 person-years, 
95% CI, 0.6 to 1.3). Of the 28 linked transmissions, only 1 occurred in the early-
therapy group (hazard ratio, 0.04; 95% CI, 0.01 to 0.27; P<0.001). Subjects receiving 
early therapy had fewer treatment end points (hazard ratio, 0.59; 95% CI, 0.40 to 
0.88; P = 0.01).
Conclusions
The early initiation of antiretroviral therapy reduced rates of sexual transmission of 
HIV-1 and clinical events, indicating both personal and public health benefits from 
such therapy. (Funded by the National Institute of Allergy and Infectious Diseases 
and others; HPTN 052 ClinicalTrials.gov number, NCT00074581.)
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Combination antiretroviral thera-py decreases the replication of human im-munodeficiency virus type 1 (HIV-1) and 
improves the survival of infected persons.1,2 Such 
therapy has been shown to reduce the amount of 
HIV-1 in genital secretions.3-5 Because the sexual 
transmission of HIV-1 from infected persons to 
their partners is strongly correlated with concentra-
tions of HIV-1 in blood6 and in the genital tract,7 it 
has been hypothesized that antiretroviral therapy 
could reduce sexual transmission of the virus. Sev-
eral observational studies have reported decreased 
acquisition of HIV-1 by sexual partners of patients 
receiving antiretroviral therapy.8-11 These results 
have been extrapolated to suggest that the use of 
early antiretroviral therapy could reduce the spread 
of the virus in a population.12 Some ecologic stud-
ies have shown a reduction in the incidence of new 
cases of HIV-1 after expanded use of antiretroviral 
therapy.13,14
The effect of the timing of the initiation of 
antiretroviral therapy on clinical and microbiologic 
outcomes has been controversial in evaluations 
of the benefit of therapy and of the associated 
short- and long-term complications and costs. For 
many years, antiretroviral therapy was delayed un-
til a patient’s CD4 count fell below 200 cells per 
cubic millimeter, which led to frequent opportu-
nistic infections.15 Retrospective analyses of pa-
tients with HIV-1 infection who were treated in 
developed countries have suggested a benefit from 
early antiretroviral therapy,16-18 although the abil-
ity to control for bias in these studies has limits.
To evaluate the effect of combination antiretro-
viral therapy on the prevention of HIV-1 transmis-
sion to uninfected partners and on clinical events 
in infected persons, the HIV Prevention Trials Net-
work (HPTN) conducted a multicontinent, ran-
domized, controlled trial, called HPTN 052, to 
compare early versus delayed antiretroviral ther-
apy for patients with HIV-1 infection who had 
CD4 counts between 350 and 550 cells per cubic 
millimeter and who were in a stable sexual rela-
tionship with a partner who was not infected.
Me thods
Study Population
We enrolled HIV-1 serodiscordant couples at 13 sites 
in 9 countries (Gaborone, Botswana; Kisumu, Ke-
nya; Lilongwe and Blantyre, Malawi; Johannesburg 
and Soweto, South Africa; Harare, Zimbabwe; Rio 
de Janeiro and Porto Alegre, Brazil; Pune and Chen-
nai, India; Chiang Mai, Thailand; and Boston). A 
pilot phase started in April 2005, and enrollment 
took place from June 2007 through May 2010. Cou-
ples were required to have had a stable relation-
ship for at least 3 months, to have reported three 
or more episodes of vaginal or anal intercourse 
during this time, and to be willing to disclose their 
HIV-1 status to their partner. Patients with HIV-1 
infection were eligible if their CD4 count was be-
tween 350 and 550 cells per cubic millimeter and 
they had received no previous antiretroviral therapy 
except for short-term prevention of mother-to-child 
transmission of HIV-1. (Full criteria for inclusion 
and exclusion are provided in the Supplementary 
Appendix, available with the full text of this article 
at NEJM.org.)
The study protocol, which is also available at 
NEJM.org, was approved by at least one local insti-
tutional review board affiliated with each site, by 
boards affiliated with collaborating organizations, 
and by other local regulatory bodies when appro-
priate (for details, see the Supplementary Appen-
dix). All study participants provided written in-
formed consent in their local languages, or English, 
if preferred.
Study Oversight
The study was funded by the National Institute of 
Allergy and Infectious Diseases (NIAID) of the 
National Institutes of Health, which assumed all 
sponsor responsibilities through an investigation-
al new drug application with the Food and Drug 
Administration (FDA). The antiviral agents that 
were used in the study were donated by pharma-
ceutical companies, which were not involved in the 
design or management of the study. All authors 
vouch for the completeness and accuracy of the 
data presented, as well as the fidelity of the report 
to the study protocol.
Study Design
HIV-1 serodiscordant couples were randomly as-
signed in a 1:1 ratio to either an early or delayed 
strategy for receipt of antiretroviral therapy. Per-
muted-block randomization was used with strat-
ification according to site. In the early-therapy 
group, antiretroviral therapy was initiated in the 
partner with HIV-1 infection at enrollment. In the 
delayed-therapy group, therapy was initiated after 
two consecutive measurements in which the CD4 
count was 250 cells per cubic millimeter or less or 
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after the development of an illness related to the 
acquired immunodeficiency syndrome (AIDS). 
HIV-1–infected participants who had active tuber-
culosis were excluded, and isoniazid prophylaxis 
was available, according to local guidelines and 
practice standards.
After enrollment, study participants were asked 
to attend three monthly visits, which were fol-
lowed by quarterly visits unless they became ill 
or needed additional antiretroviral medications. 
HIV-1–infected participants who were receiving 
antiretroviral therapy had one additional visit 
2 weeks after starting therapy. HIV-1–uninfected 
partners were encouraged to return for all visits 
together for counseling on risk reduction and 
the use of condoms, for treatment of sexually 
transmitted infections, and for management of 
other medical conditions. Some HIV-1–infected 
participants received trimethoprim–sulfamethoxa-
zole prophylaxis, according to local guidelines.
HIV-1–uninfected partners were tested for 
HIV-1 seroconversion on a quarterly basis. Samples 
from all seroconversion events were evaluated at a 
central laboratory, and results were reviewed by an 
independent HIV end-point committee. Partners 
with seroconversion were released from the study 
and referred to a prearranged local clinic for care.
After the initiation of antiretroviral therapy, 
virologic failure for HIV-1–infected participants 
was defined as two consecutive plasma HIV-1 RNA 
measurements of more than 1000 copies per mil-
liliter at 16 weeks or later. Assessment for clinical 
signs and symptoms, laboratory measurements, 
interviews about sexual behavior, review of ad-
herence to the antiretroviral regimen (including 
a self-reported questionnaire and pill counts), and 
adherence counseling were conducted at each visit. 
(Details regarding study procedures, including 
guidelines for adherence counseling, are provided 
in the Supplementary Appendix.)
Any woman who was pregnant at enrollment 
or became pregnant was provided antiretroviral 
therapy appropriate for use during pregnancy at 
the start of the second trimester. On the basis of 
the judgment of the site investigator, women in the 
delayed-therapy group discontinued antiretrovi-
ral therapy after delivery or when breast-feeding 
ended. A new partner could be enrolled with an 
HIV-1–infected participant if the original partner 
was released from the study and the new HIV-1–
uninfected partner met all inclusion or exclusion 
criteria.
Antiretroviral Drugs
Study drugs included a combination of lamivudine 
and zidovudine (Combivir), efavirenz, atazanavir, 
nevirapine, tenofovir, lamivudine, zidovudine, di-
danosine, stavudine, a combination of lopinavir 
and ritonavir (Kaletra and Aluvia), ritonavir, and a 
combination of emtricitabine and tenofovir (Tru-
vada). A prespecified combination of these drugs 
was provided to participants at monthly or quar-
terly visits. Sites could also use locally supplied, 
FDA-approved drugs if they could be purchased 
with nonstudy funds. For participants with viro-
logic failure, specified second-line treatment regi-
mens were provided.
Assessment of Linkage of Seroconversions
To assess whether seroconversions were linked, 
HIV-1 pol gene sequences were generated by pop-
ulation sequencing for study-partner pairs and for 
10 additional HIV-infected local control subjects for 
each relevant site. Sequences were analyzed with 
the use of phylogenetic methods. The probability 
of linkage was also assessed with the use of 
Bayes’ theorem to compare the genetic similarity 
of HIV-1 from partner pairs with the genetic sim-
ilarity of HIV-1 from local control subjects. In some 
cases, HIV-1 samples from partner pairs were ana-
lyzed with the use of ultra-deep pyrosequencing 
of the gp41 region.19
Statistical Analysis
We determined that an enrollment of 1750 sero-
discordant couples would provide a power of at 
least 87% to detect a 39% reduction in the inci-
dence of HIV-1 transmission to uninfected part-
ners in the early-therapy group, as compared with 
the delayed-therapy group (primary prevention end 
point). By the end of the trial, we anticipated a 
total of 188 transmission incidences, with cumu-
lative incidence rates of 8.3% in the early-therapy 
group and 13.2% in the delayed-therapy group, for 
a total duration of 6.5 years, with an accrual peri-
od of 1.5 years and a 5% annual loss to follow-up. 
The sample size of 1750 would also provide a pow-
er of 92% to show that early initiation of antiret-
roviral therapy provided at least a 20% reduction 
in the rate of serious clinical events associated with 
HIV-1 infection, which included death, a World 
Health Organization (WHO) stage 4 event, or a se-
vere bacterial infection or pulmonary tuberculosis 
(primary clinical end point). By the end of the trial, 
we anticipated a total of 234 such clinical events, 
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with cumulative incidence rates of 8.7% in the 
early-therapy group and 18.0% in the delayed-
therapy group.
The study was reviewed twice each year by an 
independent NIAID multinational data and safe-
ty monitoring board. To guide the board in its 
recommendations regarding trial continuation, a 
composite monitoring end point was developed to 
include the occurrence of either death or WHO 
stage 4 events (excluding esophageal candidiasis) 
in HIV-1–infected participants or the transmission 
of HIV-1 to uninfected partners, whichever oc-
curred first in the discordant couple. These were 
the events that were considered to have the great-
est clinical effect on both the HIV-1–infected par-
ticipant and the uninfected partner. A Lan–DeMets 
implementation of an O’Brien–Fleming monitor-
ing boundary was used to evaluate the interim data 
with respect to this composite end point.20,21 An 
early termination would be indicated if there were 
conclusive evidence to rule out a hazard ratio of 
0.80 or more in the early-therapy group. Interim 
analyses were planned when approximately 25%, 
50%, 75%, and 100% of a total 340 composite 
events were observed.
We used the Kaplan–Meier method to calculate 
event-free probabilities and person-year analysis for 
incidence rate for a given year. We also used Cox 
regression to estimate relative risks, which were 
expressed as hazard ratios and 95% confidence 
intervals, and to provide adjustment for potential 
prognostic factors, such as the infected partici-
pant’s baseline CD4 count, baseline plasma HIV-
1 RNA concentration, and sex. The same Cox 
analyses were performed on linked transmis-
sions, any transmissions, clinical events, and com-
posite monitoring events. We used chi-square tests 
to compare the frequencies of adverse events. A 
P value of less than 0.05 was considered to indi-
cate statistical significance. The cutoff was ad-
justed for multiple comparisons in trial-monitoring 
boundaries.
R esult s
Study Participants
A total of 10,838 persons were screened in order 
to enroll 1763 HIV-1–serodiscordant couples; 886 
couples were randomly assigned to the early-ther-
apy group and 877 to the delayed-therapy group) 
(Fig. 1, and the Supplementary Appendix). Twelve 
additional HIV-1–uninfected partners were enrolled 
as the result of a new relationship.
The majority of couples (97%) were heterosex-
ual, and 94% were married; 50% of HIV-1–infected 
participants were men. The majority of partici-
pants (61%) were between 26 and 40 years of age. 
At enrollment, 1291 of HIV-1–infected participants 
(73%) and 1281 of HIV-1–uninfected partners 
(72%) reported having had at least one sexual 
encounter during the previous week. During the 
same period, 5% and 6%, respectively, reported 
having unprotected sex. The median CD4 counts 
for the HIV-1–infected partners were 442 cells per 
cubic millimeter in the early-therapy group and 
428 cells per cubic millimeter in the delayed-ther-
apy group. The median log10 plasma viral load 
was 4.4 in each study group. Participants in 
the two study groups were similar in educational 
status, self-reported sexual behavior, and rate of 
condom use (Table 1).
At enrollment, less than 5% of participants had 
a sexually transmitted infection, and rates and 
types of infection were similar in the two study 
groups (see the Supplementary Appendix). A to-
tal of 84 of 449 HIV-uninfected male partners 
(19%) in the early-therapy group and 64 of 460 
(14%) in the delayed-therapy group had been cir-
cumcised (P = 0.05). New sexually transmitted in-
fections were detected with similar frequency 
among participants in the early-therapy group and 
the delayed-therapy group during the study, with 
36 and 34 syphilis infections, 6 and 8 gonorrhea 
infections, 10 and 11 chlamydia infections, and 
22 and 19 trichomonas infections, respectively. 
Among HIV-1–infected participants, a mean of 
96% of those in the early-therapy group and 95% 
of those in the delayed-therapy group reported 
100% condom use during the study.
On April 28, 2011, the data and safety moni-
toring board recommended that the results of the 
study be released on the basis of data collection 
through February 21, 2011. At that time, 90% of 
couples remained enrolled in the study, with a 
median follow-up of 1.7 years; the total number of 
person-years of follow-up was 1585 in the early-
therapy group and 1567 in the delayed-therapy 
group. The expected effect of early versus delayed 
antiretroviral therapy on log10 plasma viral load 
and CD4 counts in the HIV-1–infected participants 
was observed shortly after enrollment. By 3 months 
after randomization, 89% of the participants in 
the early-therapy group had a plasma viral load of 
less than 400 copies per milliliter, as compared 
with 9% in the delayed-therapy group. CD4 counts 
in the early-therapy group rose after the initia-
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1763 Couples underwent randomization
(including 82 couples from run-in study)
3526 Were identified as 1763 eligible
HIV-serodiscordant couples
10,838 Patients were screened
7312 Were excluded
3058 Were HIV-positive but were ineligible
owing to CD4 count
2565 Were HIV-negative but HIV-positive partner
was ineligible
308 Were HIV-positive with HIV-positive partner
155 Were ineligible owing to sexual history
1226 Had other reason
886 Couples were assigned
to early-therapy group
877 Couples were assigned
to delayed-therapy group
7 New HIV-1–uninfected
partners were enrolled
2 Partners were HIV-
positive at enrollment
5 New HIV-1–uninfected
partners were enrolled
2 Partners were HIV-
positive at enrollment
893 Partners were enrolled for HIV-1
transmission analysis
882 Partners were enrolled for HIV-1
transmission analysis 
Semiannual-visit attendance
Month 6
Month 12
Month 18
Month 24
Month 30
Month 36
Month 42
809/874
720/800
509/601
340/393
230/267
113/129
43/50
93%
90%
85%
87%
86%
88%
86%
Semiannual-visit attendance
Month 6
Month 12
Month 18
Month 24
Month 30
Month 36
Month 42
803/873
727/800
535/612
346/399
231/267
122/135
49/54
92%
91%
87%
87%
87%
90%
91%
22 (2%) Partners had no follow-up
5 (1%) Died
9 (1%) Declined further participation
1 (<1%) Was unable to adhere to
visit schedule
3 (<1%) Relocated
2 (<1%) Were unable to be contacted
31 (3%) Ended relationship
4 (<1%) Had other reason
31 (4%) Partners had no follow-up
4 (<1%) Died
13 (1%) Declined further participation
3 (<1%) Were unable to adhere to
visit schedule
3 (<1%) Relocated
2 (<1%) Were unable to be contacted
42 (5%) Ended relationship
1 (<1%) Had other reason
Figure 1. Enrollment and Outcomes.
This trial profile describes recruitment of couples from the general population, randomization, HIV-1–uninfected 
partner’s enrollment, seroconversion at baseline, retention, and loss-to-follow-up for assessment of the primary end 
point of linked HIV-1 transmission. Enrolled partners were followed on a quarterly-visit schedule, although atten-
dance at semiannual visits is shown.
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tion of antiretroviral therapy, from a median of 
442 cells per cubic millimeter at enrollment to 
603 cells per cubic millimeter by 12 months, and 
the counts continued to rise throughout the follow-
up period (see the Supplementary Appendix). A 
modest decline in CD4 counts was observed in the 
delayed-therapy group, from a median of 428 cells 
per cubic millimeter at enrollment to 399 cells per 
cubic millimeter by 12 months. A total of 21% of 
HIV-1–infected participants in the delayed-therapy 
group began taking antiretroviral therapy after 
a median of 42 months. Among all participants, 
72% received a combination of zidovudine, lamivu-
dine, and efavirenz (see the Supplementary Appen-
Table 1. Baseline Characteristics of the Participants.*
Characteristic HIV-1–Infected Participants HIV-1–Uninfected Participants†
Early Therapy
(N = 886)
Delayed Therapy
(N = 877)
Early Therapy
(N = 893)
Delayed Therapy
(N = 882)
Demographic
Female sex — no. (%) 432 (49) 441 (50) 441 (49) 418 (47)
Age group — no. (%)
18–25 yr 145 (16) 161 (18) 154 (17) 174 (20)
26–40 yr 556 (63) 547 (62) 537 (60) 526 (60)
>40 yr 185 (21) 169 (19) 202 (23) 182 (21)
Education level — no. (%)
No schooling 101 (11) 69 (8) 112 (13) 77 (9)
Primary schooling 360 (41) 347 (40) 317 (35) 344 (39)
Secondary schooling 346 (39) 388 (44) 373 (42) 367 (42)
Postsecondary schooling 79 (9) 72 (8) 91 (10) 93 (11)
Missing data 0 1 (<1) 0 1 (<1)
Marital status — no. (%)
Single 49 (6) 38 (4) 53 (6) 43 (5)
Married or living with partner 833 (94) 833 (95) 834 (93) 833 (94)
Widowed, separated, or divorced 4 (<1) 6 (1) 6 (1) 6 (1)
Region — no. (%)
North or South America 142 (16) 136 (16) 145 (16) 139 (16)
Asia 267 (30) 264 (30) 268 (30) 264 (30)
Africa 477 (54) 477 (54) 480 (54) 479 (54)
Sexual activity — no. (%)
Any unprotected sex in past week 37 (4) 51 (6) 49 (5) 53 (6)
No. of sex partners in past 3 mo
0–1 831 (94) 833 (95) 863 (97) 844 (96)
2–4 48 (5) 41 (5) 29 (3) 36 (4)
>4 7 (1) 2 (<1) 1 (<1) 1 (<1)
Missing data 0 1 (<1) 0 1 (<1)
No. of sexual encounters in past week
0 246 (28) 225 (26) 253 (28) 240 (27)
1–2 430 (49) 438 (50) 410 (46) 433 (49)
3–4 156 (18) 158 (18) 180 (20) 151 (17)
>4 54 (6) 55 (6) 50 (6) 57 (6)
Missing data 0 1 (<1) 0 1 (<1)
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dix). Adherence to the study regimen of at least 
95% (as measured by pill count) was observed in 
79% of participants in the early-therapy group and 
in 74% of those in the delayed-therapy group. 
Details with respect to regimens of antiretroviral 
therapy and pill counts are provided in the Sup-
plementary Appendix.
Virologic failure was observed in 45 of 886 
participants (5%) in the early-therapy group and 
in 5 of 184 participants in the delayed-therapy 
group who initiated antiretroviral therapy (3%) 
(P = 0.23). Of all treated participants, 66% initiated 
a second-line regimen.
Primary Prevention Outcome
A total of 39 HIV-1 transmission events were ob-
served (incidence rate, 1.2 per 100 person-years; 
95% confidence interval [CI], 0.9 to 1.7), with 
4 events in the early-therapy group (incidence rate, 
0.3 per 100 person-years; 95% CI, 0.1 to 0.6) and 
35 events in the delayed-therapy group (incidence 
rate, 2.2 per 100 person-years; 95% CI, 1.6 to 3.1), 
for a hazard ratio in the early-therapy group of 
0.11 (95% CI, 0.04 to 0.32; P<0.001) (Table 2 and 
Fig. 2; also see the Supplementary Appendix for 
details regarding the incidence of transmission). 
Through viral genetic analysis, 28 transmissions 
were linked to the HIV-1–infected participant (in-
cidence rate, 0.9 per 100 person-years; 95% CI, 
0.6 to 1.3), with 1 transmission in the early-therapy 
group (incidence rate, 0.1 per 100 person-years; 
95% CI, 0.0 to 0.4) and 27 transmissions in the 
delayed-therapy group (incidence rate, 1.7 per 
100 person-years; 95% CI, 1.1 to 2.5), for a hazard 
ratio in the early-therapy group of 0.04 (95% CI, 
0.01 to 0.27; P<0.001). The remaining 11 trans-
missions (3 in the early-therapy group and 8 in the 
delayed-therapy group) included 7 transmissions 
that were unlinked (3 in the early-therapy group 
and 4 in the delayed-therapy group), 3 transmis-
Table 1. (Continued.)
Characteristic HIV-1–Infected Participants HIV-1–Uninfected Participants†
Early Therapy
(N = 886)
Delayed Therapy
(N = 877)
Early Therapy
(N = 893)
Delayed Therapy
(N = 882)
Clinical
CD4 count — no./mm3
Median 442 428 
Interquartile range 373–522 357–522 NA NA
Plasma RNA viral load — no. (%)
<400 copies/ml 54 (6) 43 (5) NA NA
400–1000 copies/ml 24 (3) 33 (4) NA NA
1001–10,000 copies/ml 212 (24) 183 (21) NA NA
10,001–100,000 copies/ml 407 (46) 432 (49) NA NA
100,001–1 million copies/ml 186 (21) 186 (21) NA NA
Missing data 3 (<1) 4 (<1) NA NA
Women reporting previous antiretroviral 
therapy during pregnancy
— no./total no. (%)
115/432 (27) 119/441 (27) NA NA
Type of serodiscordancy — no. (%)
HIV-positive man, HIV-negative woman 436 (49) 417 (48) NA NA
HIV-positive woman, HIV-negative man 431 (49) 441 (50) NA NA
HIV-positive man, HIV-negative man 18 (2) 19 (2) NA NA
HIV positive woman, HIV-negative 
woman
1 (<1) 0 NA NA
* Data regarding the incidence of sexually transmitted infections are provided in the Supplementary Appendix. HIV denotes 
human immunodeficiency virus, and NA not applicable.
† Some participants with HIV-1 infection had more than one uninfected partner during the study period.
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sions that could not be classified on the basis of 
available data, and 1 transmission that has not yet 
been evaluated. The latter 4 transmissions were 
all in the delayed-therapy group.
The rate of transmission events in the delayed-
therapy group was relatively constant across the 
first 3 years of study follow-up for both linked 
and any transmissions. Of the 28 HIV-1–infected 
participants who had linked transmission to a 
partner, 17 (61%) had a CD4 count of more than 
350 cells per cubic millimeter at the study visit 
before the detection of linked HIV-1 transmission. 
The single linked transmission in the early-therapy 
group was identified 3 months after the HIV-1– 
infected participant initiated treatment; all linked 
transmissions in the delayed-therapy group oc-
curred while the HIV-1–infected participant was 
not receiving antiretroviral therapy. The Kaplan–
Meier curves for both linked and any transmis-
sions show immediate and sustained reduction in 
the risk of HIV-1 transmission after the initiation 
of antiretroviral therapy (Fig. 2).
Of the 28 linked transmissions, 23 (82%) oc-
curred at African sites. HIV-1–infected women 
were the source of infection in 18 of 27 (67%) 
linked transmissions in the delayed-therapy group, 
Table 2. Incidence of Partner-Linked and Any HIV-1 Transmission and Clinical and Composite Events.
Variable Early Therapy Delayed Therapy
Hazard or Rate Ratio 
(95% CI)*
Events Person-yr
Rate 
(95% CI) Events Person-yr
Rate 
(95% CI)
no. % no. %
Linked transmission
Total 1 1585.3 0.1 (0.0–0.4) 27 1567.3 1.7 (1.1–2.5) 0.04 (0.01–0.27)
1 yr 1 819.0 0.1 (0.0–0.7) 16 813.3 2.0 (1.1–3.2) 0.06 (0.00–0.40)
2–3 yr 0 686.5 0.0 (0.0–0.5) 9 682.8 1.3 (0.6–2.5) 0.00 (0.00–0.50)
>3 yr 0 79.9 0.0 (0.0–4.6) 2 71.2 2.8 (0.3–10.1) 0.00 (0.00–4.75)
Any transmission†
Total 4 1585.3 0.3 (0.1–0.6) 35 1567.3 2.2 (1.6–3.1) 0.11 (0.04–0.32)
1 yr 2 819.0 0.2 (0.0–0.9) 18 813.3 2.2 (1.3–3.5) 0.11 (0.01–0.46)
2–3 yr 2 686.5 0.3 (0.0–1.1) 14 682.8 2.1 (1.1–3.4) 0.14 (0.02–0.62)
>3 yr 0 79.9 0.0 (0.0–4.6) 3 71.2 4.2 (0.9–12.3) 0.00 (0.00–2.16)
Clinical events‡
Total 40 1661.9 2.4 (1.7–3.3) 65 1641.8 4.0 (3.1–5.0) 0.59 (0.40–0.88)
1 yr 29 831.0 3.5 (2.3–5.0) 39 832.6 4.7 (3.3–6.4) 0.75 (0.44–1.24)
2–3 yr 9 739.8 1.2 (0.6–2.3) 21 725.7 2.9 (1.8–4.4) 0.42 (0.17–0.96)
>3 yr 2 91.1 2.2 (0.3–7.9) 5 83.6 6.0 (1.9–14.0) 0.37 (0.04–2.24)
Composite events§
Total 23 1700.1 1.4 (0.9–2.0) 79 1642.0 4.8 (3.8–6.0) 0.28 (0.18–0.45)
1 yr 13 843.7 1.5 (0.8–2.6) 47 833.9 5.6 (4.1–7.5) 0.27 (0.14–0.51)
2–3 yr 8 763.8 1.0 (0.5–2.1) 26 732.5 3.5 (2.3–5.2) 0.30 (0.12–0.67)
>3 yr 2 92.6 2.2 (0.3–7.8) 6 75.5 7.9 (2.9–17.3) 0.27 (0.03–1.52)
* Hazard ratios were calculated with the use of unstratified univariate Cox regression analysis on an intention-to-treat 
 basis. Year-specific rate ratios were calculated on the basis of the person-year analysis. P<0.001 for the between-group 
comparison for linked transmission, P<0.001 for all transmission, P = 0.01 for clinical events, and P<0.001 for composite 
events, with all comparisons favoring early therapy.
† Any transmission includes all transmission events observed during follow-up, regardless of their linkage between partners.
‡ Clinical events include death, World Health Organization stage 4 events, severe bacterial infections, and pulmonary tuber-
culosis for index partners.
§ Composite events include death or World Health Organization stage 4 events (excluding esophageal candidiasis) for 
the index partner or HIV transmission to the uninfected partner, whichever occurred earlier.
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and a man was the source of the single transmis-
sion in the early-therapy group. Women were the 
HIV-1–infected participant in 58% of African cou-
ples. A high viral load in blood plasma of infected 
participants at baseline increased the risk of 
HIV-1 transmission (Table 3). The median plas-
ma viral load in 27 participants at the visit most 
proximal to the detection of HIV-1 transmission 
was 4.9 log10 (range, 2.6 to 5.8). Conversely, self-
reported 100% condom use at baseline was associ-
ated with a reduced risk of HIV-1 transmission. In 
the stratified multivariate analysis according to 
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Figure 2. Kaplan–Meier Estimates for Partner-Linked and Any HIV-1 Transmission and for Clinical and Composite Monitoring Events.
Shown are Kaplan–Meier estimates for the cumulative probabilities of linked HIV-1 transmission between partners (Panel A), any HIV 
transmission (Panel B), clinical events (Panel C), and composite monitoring events (Panel D) among participants in the early-therapy 
and delayed-therapy groups.
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site, the adjusted hazard ratio for linked transmis-
sion in the early-therapy group was 0.04 (95% CI, 
0.01 to 0.28; P<0.001) (Table 3).
Primary Treatment Outcome
A total of 105 treatment end points, as measured 
by the first serious HIV-1–related clinical event or 
death, were observed in HIV-1–infected partici-
pants: 40 in the early-therapy group and 65 in the 
delayed-therapy group (hazard ratio, 0.59; 95% CI, 
0.40 to 0.88; P = 0.01 (Table 2, and the Supplemen-
tary Appendix). Of such clinical events, 44% oc-
curred in Asia and 45% in Africa. The baseline 
plasma viral load was an important predictor of 
clinical events, as assessed on multivariate analy-
sis (Table 3). In the stratified multivariate model, 
the adjusted hazard ratio for clinical events in the 
early-therapy group was 0.59 (95% CI, 0.40 to 0.89). 
The difference in the rate of clinical events ap-
peared to be driven mainly by the incidence of 
extrapulmonary tuberculosis, which developed 
in 3 participants in the early-therapy group and 
17 in the delayed-therapy group (P = 0.002); of these 
cases, 55% were observed in India. Pulmonary tu-
berculosis was observed in 13 participants in the 
early-therapy group and 15 in the delayed-therapy 
group; isoniazid prophylaxis was administered 
to only 4% of participants in each study group. 
There were 23 deaths during the course of the 
study, 10 in the early-therapy group and 13 in the 
delayed-therapy group (hazard ratio, 0.77; 95% CI, 
0.34 to 1.76; P = 0.27) (for details regarding causes 
of death, see the Supplementary Appendix).
Composite Monitoring Events
Among 102 composite monitoring events, there 
were 39 transmission events in which the sexual 
partner acquired HIV-1. Among HIV-1–infected 
participants, 21 died and 42 had WHO stage 4 clin-
ical events. Of these monitoring events, 58 (57%) 
occurred in Africa, 31 (30%) in Asia, and 13 (13%) 
in the Americas. Overall, 23 monitoring events 
were observed in the early-therapy group and 79 
in the delayed-therapy group (hazard ratio, 0.28; 
95% CI, 0.18 to 0.45; P<0.001) (Table 2). Accord-
ing to the monitoring guidelines that were based 
on the Lan–DeMets implementation of O’Brien–
Fleming boundaries, the computed z statistic was 
4.43, which exceeded the prespecified cutoff of 
3.93 and thus ruled out the hypothesis that early 
Table 3. Hazard Ratios for Prognostic Factors for Partner-Linked and Any HIV-1 Transmission and for Clinical 
and Composite Events.*
Variable
Linked 
 Transmission
Any 
 Transmission
Clinical 
Events
Composite 
Events
hazard ratio (95% CI)
Univariate analysis
Early therapy vs. delayed therapy 0.04 (0.01–0.26) 0.11 (0.04–0.32) 0.60 (0.41–0.90) 0.28 (0.18–0.45)
Baseline CD4 count (per 100 CD4 
i ncrement)
1.27 (1.02–1.59) 1.25 (1.02–1.52) 0.84 (0.70–1.00) 1.06 (0.91–1.24)
Baseline viral load (per unit log10 
 increment)
1.96 (1.17–3.27) 1.66 (1.08–2.55) 1.74 (1.32–2.30) 1.51 (1.15–1.97)
Male sex vs. female sex 0.69 (0.31–1. 52) 0.88 (0.45–1.71) 1.61 (1.05–2.48) 1.18 (0.78–1.78)
Baseline condom use (100% vs. <100%) 0.35 (0.14–0.88) 0.47 (0.19–1.14) NA 0.68 (0.29–1.60)
Multivariate analysis
Early therapy vs. delayed therapy 0.04 (0.01–0.28) 0.11 (0.04–0.33) 0.59 (0.40–0.89) 0.28 (0.18–0.45)
Baseline CD4 count (per 100 CD4 
 increment)
1.24 (1.00–1.54) 1.22 (1.02–1.47) 0.90 (0.75–1.08) 1.11 (0.96–1.28)
Baseline viral load (per unit log10 
 increment)
2.85 (1.51–5.41) 2.13 (1.30–3.50) 1.65 (1.24–2.20) 1.60 (1.21–2.11)
Male sex vs. female sex 0.73 (0.33–1.65) 1.00 (0.51–1.97) 1.46 (0.95–2.26) 1.18 (0.78–1.80)
Baseline condom use (100% vs. <100%) 0.33 (0.12–0.91) 0.41 (0.16–1.08) NA 0.64 (0.27–1.52)
* Hazard ratios were calculated with the use of univariate and multivariate Cox regression analysis, stratified according to 
study site. The results are similar to those calculated with the use of unstratified Cox regression analysis, which are not 
shown. NA denotes not applicable.
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therapy would provide at most a 20% reduction in 
the risk of the composite monitoring end point.
Adverse Events
After the exclusion of primary clinical end points 
(death, WHO stage 4 events, pulmonary tubercu-
losis, and severe bacterial infections), 246 HIV-1–
infected participants had one or more severe or 
life-threatening adverse events (grade 3 or 4): 127 
of 886 (14%) were in the early-therapy group and 
119 of 877 (14%) were in the delayed-therapy 
group (P = 0.64). The most frequently reported ad-
verse events included infections, psychiatric and 
nervous system disorders, metabolism and nutri-
tion disorders, and gastrointestinal disorders (for 
details, see the Supplementary Appendix). Grade 
3 or 4 laboratory abnormalities during study fol-
low-up occurred in 242 participants (27%) in the 
early-therapy group and 161 participants (18%) 
in the delayed-therapy group (P<0.001). The most 
frequent laboratory abnormalities included neutro-
penia, abnormal phosphate level, and total biliru-
bin elevations (with bilirubin elevations observed 
primarily in participants taking atazanavir as part 
of their drug regimen) (see the Supplementary 
Appendix).
Discussion
In this study involving 1763 serodiscordant cou-
ples in which HIV-1–infected participants had a 
CD4 count of 350 to 550 cells per cubic millime-
ter, there was a relative reduction of 96% in the 
number of linked HIV-1 transmissions resulting 
from the early initiation of antiretroviral therapy, as 
compared with delayed therapy. There was a relative 
reduction of 89% in the total number of HIV-1 
transmissions resulting from the early initiation 
of antiretroviral therapy, regardless of viral link-
age with the infected partner. The sustained sup-
pression of HIV-1 in genital secretions resulting 
from antiretroviral therapy is the most likely mech-
anism for the prevention of HIV-1 transmission that 
we observed.4,5
The majority of HIV-1 transmissions (82%) were 
observed in Africa. This result reflects not only the 
large number of study participants who were en-
rolled in this region (54%) but also other factors 
that increase the probability of HIV-1 transmission 
among African couples. Several groups have re-
ported higher viral loads in patients with HIV-1 
infection in sub-Saharan Africa than in patients in 
developed countries.22,23 Clade C HIV-1, the domi-
nant type in southern Africa, may have other trans-
mission advantages as well.24 More frequent sexual 
encounters and limited condom use would also 
favor increased HIV transmission among African 
couples, possibilities that are being evaluated.
Although HIV-1 transmission from patients 
with acute and early HIV-1 infection and advanced 
HIV-1 disease and the acquired immunodeficiency 
syndrome (AIDS)25 appears to be most efficient,26 
the results from this and other studies9 emphasize 
that HIV-1 can be transmitted from infected per-
sons who are asymptomatic or minimally symp-
tomatic and who have high CD4 counts. Since 
most persons with established HIV-1 infection fall 
into the latter category, such transmission, albeit 
not maximally efficient, must help fuel the spread 
of HIV-1.
Early antiretroviral therapy was associated with 
a relative reduction of 41% in the number of HIV-
1–related clinical events, which suggests a clinical 
benefit for the initiation of antiretroviral therapy 
when a person has a CD4 count of 350 to 550 cells 
per cubic millimeter, as compared with therapy 
that is delayed until the CD4 count falls into the 
range of 200 to 250 cells per cubic millimeter. In 
contrast to a recent trial15 comparing the effect of 
the initiation of therapy in patients with a CD4 
count ranging from 200 to 350 cells per cubic mil-
limeter with those with a count below 200 cells 
per cubic millimeter, we did not detect a signifi-
cant between-group difference in overall mortality. 
Despite our relatively short follow-up period, the 
magnitude of the clinical effect we observed was 
similar to that seen in observational studies con-
ducted in the developed world.16-18 The difference 
between the early-therapy group and the delayed-
therapy group was driven largely by the diagnosis 
of extrapulmonary tuberculosis, with the majority 
of these cases occurring in India. The use of iso-
niazid prophylaxis, although recommended by the 
WHO for patients with HIV-1 infection,27 was in-
frequently prescribed for participants in this study. 
In addition, data from observational studies fo-
cusing on HIV-1–related and non–HIV-1–related 
clinical events and CD4 counts have led to the 
hypothesis that delayed antiretroviral therapy could 
ultimately lead to an increased rate of clinical 
events, regardless of subsequent therapy.28 How-
ever, we cannot evaluate this possibility without a 
longer period of follow-up.
We noted more adverse events in the early-
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therapy group than in the delayed-therapy group, 
including more adverse events related to antiretro-
viral therapy. The clinical importance of the labo-
ratory abnormalities that were responsible for this 
difference is unclear. Further examination of these 
data and additional longitudinal follow-up will be 
important to better understand the clinical and 
public health benefits of early antiretroviral ther-
apy, as compared with drug costs and side effects.
Our study has several limitations. In order to 
examine the effects of antiretroviral therapy on 
HIV-1 transmission, we studied stable HIV-1–dis-
cordant couples, who may not be entirely repre-
sentative of the general population.29 We provided 
ongoing couples counseling and condoms, which 
probably contributed to the low incidence of HIV-1 
infection, as previously reported.30 Some partici-
pants received trimethoprim–sulfamethoxazole 
and isoniazid prophylaxis at the discretion of the 
investigators, which could have reduced the de-
gree of benefit observed with early antiretroviral 
therapy.31
In conclusion, the biologic plausibility of the 
use of antiretroviral therapy for the prevention 
of HIV-1 infection has been carefully examined 
during the past two decades.32 The idea of HIV-1 
treatment as prevention has garnered tremendous 
interest and hope33 and inspired a series of pop-
ulation-level HIV-1 treatment-as-prevention studies 
that are now in the pilot or planning stages.34,35 
Such interventions are based on the hypothesis 
that the use of antiretroviral therapy reliably pre-
vents HIV-1 transmission over an extended peri-
od of time. In this trial, we found that early anti-
retroviral therapy had a clinical benefit for both 
HIV-1–infected persons and their uninfected 
sexual partners. These results support the use 
of antiretroviral treatment as a part of a public 
health strategy to reduce the spread of HIV-1 
infection.
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